Quantitative Imaging Tools for Lung Cancer Drug Assessment

Mulshine

ISBN 10: 0470118806 / ISBN 13: 9780470118801

Published by John Wiley and Sons Ltd, 2008

About this Item

This book presents chapters written by leading clinical researchers in the field of lung cancer, where high resolution 3-D imaging technology appears to hold the greatest near-term promise. Editor(s): Mulshine, James L.; Baer, Thomas M. Num Pages: 162 pages, Illustrations. BIC Classification: MBGR; MBNC; MJCL; MMP. Category: (P) Professional & Vocational. Dimension: 241 x 162 x 16. Weight in Grams: 436. . 2008. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.

Seller Inventory # V9780470118801

Bibliographic Details

• Title: Quantitative Imaging Tools for Lung Cancer Drug Assessment
• Publisher: John Wiley and Sons Ltd
• Publication Date: 2008
• Language: English
• ISBN 10: 0470118806
• ISBN 13: 9780470118801
• Binding: Hardcover
• Condition: New

About this title

Synopsis

Presents chapters written by leading clinical researchers in the field of lung cancer, where high resolution 3-D imaging technology appears to hold the greatest near-term promise, as well as contributions from recognized experts in CAD, medical information technology systems, regulatory procedure, x-ray standards development, and clinical trial design. These expert contributors discuss the current state of the art and provide a road map for directing further research in lung cancer as well as other organ systems.

About the Author

James L. Mulshine, MD, is a Professor of Internal Medicine, Associate Provost of Research and Vice President, Rush University Medical Center in Chicago, Illinois.?In this position, Dr. Mulshine is the primary academic officer responsible for managing research activities at Rush University Medical School. He is an internationally recognized expert on lung cancer.?Over the last few years, Dr. Mulshine has been working with a range of organizations to accelerate the use of high resolution spiral CT in the quantitative evaluation of drug response for early lung cancer.